tislelizumab + etoposide + cisplatin

Tislelizumab + etoposide + cisplatin is a multi-agent regimen primarily investigated as first-line therapy for **extensive-stage small cell lung cancer (ES-SCLC)**. The regimen combines: - **Tislelizumab**, a humanized IgG4 monoclonal antibody targeting the **Programmed Cell Death Protein 1 (PD-1)**, thereby blocking an immune checkpoint and promoting T-cell mediated anticancer activity. - **Etoposide**, a small molecule chemotherapeutic that inhibits **topoisomerase II**, leading to DNA strand breaks and apoptosis in rapidly dividing tumor cells. - **Cisplatin**, a platinum-based chemotherapeutic which causes DNA crosslinks and subsequent apoptosis. Together, this combination delivers a **dual approach**: immune checkpoint blockade and cytotoxic chemotherapy. It is used intravenously, typically in cycles every three weeks. Tislelizumab + etoposide + cisplatin has shown prolonged overall survival and improved response rates in ES-SCLC when compared to chemotherapy alone, leading to regulatory submissions for first-line use in this indication[1][4].

Brand names

Tevimbra (tislelizumab)cisplatinetoposide

Other names

Tislelizumab + Cisplatin + EtoposideTevimbra + Cisplatin + Etoposide